OVID - Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday March 11
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB BChir, Chairman and Chief Executive Officer, will present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11, 2019, at 2:50 p.m. EDT. The conference will be held at the Boston Marriot Copley Place in Boston, MA.
A live audio webcast of the presentation can be accessed through the Events & Presentations section of the company's website at investors.ovidrx.com. An archived replay of the webcast will be available on the company's website for two weeks following the live presentation.
About Ovid Therapeutics
Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company using its BoldMedicineâ„¢ approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s lead investigational medicine, OV101, is currently in development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK-935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts
Investors:
Investor Relations & Public Relations
Ovid Therapeutics Inc.
irpr@ovidrx.com
Alex Gray
Burns McClellan, Inc.
agray@burnsmc.com
(212) 213-0006
Media:
Jerica Pitts
W2Opure
jpitts@purecommunications.com
(312) 858-3469